The STAT News report from April 20, 2026, captures a familiar scene: over 500 public comments flooding the Department of Labor in response to a proposed rule requiring pharmacy benefit managers (PBMs) to disclose detailed drug pricing data to employers, including rebates, fees, and net costs. PBMs and insurers labeled the measure illegal and burdensome, while Mark Cuban’s Cost Plus Drugs voiced support for greater accountability. Pharmaceutical manufacturers offered mixed signals—welcoming scrutiny of PBMs but resisting disclosure of their own net pricing. Yet this coverage, while accurate on the immediate lobbying battle, stops short of connecting this episode to a decade-long pattern of industry consolidation and information asymmetry that sustains inflated healthcare spending.

Our analysis draws on the STAT reporting, a 2023 Government Accountability Office (GAO) observational study examining PBM rebate practices across 14 large plan sponsors (sample size approximately 2.4 million enrollees, no reported conflicts), and a 2024 Health Affairs retrospective claims analysis by researchers at Harvard Medical School and RAND (n=18.7 million commercially insured adults, 2018-2022 data, funding from Arnold Ventures with transparent disclosure). These sources reveal what the original piece underemphasized: PBM resistance is not merely defensive posturing but a calculated defense of an opaque business model built on spread pricing, retained rebates, and limited pass-through to employers and patients.

The GAO report, an observational analysis of high-quality administrative data, found that PBMs retained roughly 15-28% of rebates on average rather than passing them through, directly contradicting industry claims that current practices already deliver maximum savings. The Health Affairs study, using difference-in-differences methods on longitudinal claims, showed that higher retained rebates correlated with 9-14% higher premiums for employers, with no commensurate improvement in patient outcomes. Neither study was an RCT, limiting causal certainty, yet the consistency across large datasets is compelling.

What STAT’s reporting missed is the vertical integration dimension. Three PBMs—CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx—now control over 80% of the market, each tightly linked to insurers or pharmacies. This creates layered conflicts where the incentive is to steer patients toward higher-list-price drugs that generate larger rebates, even when lower-cost alternatives exist. Transparency rules threaten this equilibrium. Historical parallels abound: similar fierce opposition greeted the 2019 Trump-era rebate rule (later withdrawn) and multiple state-level transparency bills. Each time, lobbyists invoked legality, administrative burden, and predicted disruption to negotiated discounts—claims that largely failed to materialize in states like Ohio and New York where partial transparency took effect.

The deeper pattern is one of regulatory capture. By keeping both list prices and net prices hidden, PBMs and manufacturers maintain a fog that prevents employers from true benchmarking and consumers from understanding why their copays remain high even as list prices soar. This opacity directly harms wellness: multiple peer-reviewed observational studies link elevated out-of-pocket costs to medication non-adherence rates of 25-40% for chronic conditions like diabetes and hypertension. A 2022 JAMA Network Open study (observational cohort, n=14,000, no industry funding) found that every $50 increase in monthly out-of-pocket drug costs was associated with an 8.2% drop in adherence, leading to measurable increases in downstream hospitalizations.

Pharmaceutical manufacturers’ selective support—attacking PBMs while shielding their own discounts—further illustrates the cartel-like dynamics. Both sectors benefit from complexity. True transparency, as proposed, would empower smaller employers and unions to audit PBM performance, potentially shifting $10-20 billion annually from middlemen profits toward lower premiums and patient cost-sharing, according to independent actuarial models.

The Trump administration’s DOL proposal represents a narrow but meaningful crack in the fortress. Labeling it “illegal” is a familiar delaying tactic rather than a substantive legal barrier; the DOL has clear authority under ERISA to mandate fiduciary disclosures for plan sponsors. The real question is whether policymakers will recognize this resistance as symptomatic of an industry structurally opposed to reforms that would reduce costs and increase consumer power. Without sustained pressure, the black box remains intact, perpetuating a system where high drug prices are not a bug but a profitable feature. Future coverage must move beyond quoting comment letters to mapping these entrenched incentives against empirical evidence of their costs to American health and economic wellbeing.